FIGURE 2 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Patients with MPN can adopt a Mediterranean eating pattern with dietician counseling and education. A, Percentage of participants with MEDAS scores ≥8 at each timepoint with orange shaded area depicting the active intervention period. B, Participant responses to feasibility question during active intervention period, green represents a participant who met the feasibility benchmark of HEI-2015 (C) was calculated from each 24-hour diet recall, and scores for each participant were averaged for the pre-intervention (weeks 1–2), active intervention (weeks 3–12), and post-intervention (weeks 13–15) period. Data shown represent median with interquartile range.</p

Mediterranean Diet education materials from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Educational materials given to MED diet group</p

FIGURE 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

NUTRIENT study design.</p

Supplementary Table 4 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Supplementary Table 4. Longitudinal lipid values.</p

Supplementary Figure 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Supplementary Figure 1. Complete blood count (CBC) data from participants.</p

Supplementary Table 1 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Supplementary Table 1. Inclusion and Exclusion Criteria</p

FIGURE 4 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Baseline and week 9 BMI. Baseline BMI was calculated using height and weight at enrollment, with no significant differences between USDA and MED groups. Weight was followed throughout the study, no significant changes in BMI were observed in either group.</p

Supplementary Figure 3 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Supplementary Figure 3. Changes in JAK2V617F allele burden over time.</p

FIGURE 6 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Fecal microbiome composition. A, A line plot displaying the microbial diversity, as measured by the Shannon index, of individuals over time. B, A line plot displaying the microbial composition of individuals over time. The y-axis is the first principal coordinate produced by Bray–Curtis dissimilarity ordination of the microbiome. In both A and B, the orange shaded area depicts the active intervention period and the SE is represented by error bars.</p

FIGURE 3 from The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Results from a Randomized Phase I Pilot Study for Feasibility and Adherence

Changes in symptom burden during study. A, Waterfall plots of percentage change in MPN-SAF (MPN-SAF TSS) at each week compared with baseline (baseline defined as average MPN-SAF TSS of weeks 1 and 2). B, Raw change in specific symptoms at each week compared with baseline (mean ± SD). C, Correlation between change in raw MEDAS score and change in raw MPN-SAF score from baseline to week 9 (left) or baseline to week 12 (right).</p